A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.
Who Is on the Research Team?
Joshua Friedman, MD, PhD
Principal Investigator
Spyre Therapeutics, Inc.
Are You a Good Fit for This Trial?
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants receive SPY072 + bimekizumab
Participants receive matching placebo for SPY072 + bimekizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Spyre Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.